BFC Planning’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
SL
BFC Planning's GPCR Position: Q3 2026 in Review
BFC Planning reduced its Structure Therapeutics (GPCR) stake by 50% in Q3 2026, selling an estimated $4.69K and leaving 100 shares worth $3.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2866.
BFC Planning first reported a position in GPCR in Q3 2024 and has held it in 8 quarters since. The position peaked at $13.9K in Q4 2025. 113 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- BFC Planning held 100 shares of Structure Therapeutics worth $3.13K as of Q3 2026.
- BFC Planning sold 100 Structure Therapeutics shares in Q3 2026, an estimated $4.69K.
- Structure Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2866 holding.
- BFC Planning first reported a position in Structure Therapeutics in Q3 2024 and has held it in 8 quarters since.
- BFC Planning's Structure Therapeutics position peaked at $13.9K in Q4 2025.
- 113 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.